1-2 of 2
Hongjie Zhu
Close
Sort by
Journal Articles

Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study

Clinical Trials & Observations
Emmanuel Bachy, Kerry J. Savage, Huiqiang Huang, Yok-Lam Kwong, Giuseppe Gritti, Qingyuan Zhang, Anna Marina Liberati, Junning Cao, Haiyan Yang, Siguo Hao, Jianda Hu, Keshu Zhou, Mario Petrini, Filomena Russo, Huilai Zhang, Wei Sang, Jie Ji, Andrés José María Ferreri, Gandhi Laurent Damaj, Hui Liu, Wei Zhang, Xiaoyan Ke, Chiara Ghiggi, Sha Huang, Xiaotong Li, Hui Yao, Jason Paik, William Novotny, Wenxiao Zhou, Hongjie Zhu, Pier Luigi Zinzani
Journal: Blood Advances
Blood Adv (2023) 7 (16): 4435–4447.
https://doi.org/10.1182/bloodadvances.2022009575
Published: 2023
Includes: Supplemental data
Journal Articles

Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies

Clinical Trials & Observations
Constantine S. Tam, Meletios Dimopoulos, Ramon Garcia-Sanz, Judith Trotman, Stephen Opat, Andrew W. Roberts, Roger Owen, Yuqin Song, Wei Xu, Jun Zhu, Jianyong Li, Lugui Qiu, Shirley D’Sa, Wojciech Jurczak, Gavin Cull, Paula Marlton, David Gottlieb, Javier Munoz, Tycel Phillips, Chenmu Du, Meng Ji, Lei Zhou, Haiyi Guo, Hongjie Zhu, Wai Y. Chan, Aileen Cohen, William Novotny, Jane Huang, Alessandra Tedeschi
Journal: Blood Advances
Blood Adv (2022) 6 (4): 1296–1308.
https://doi.org/10.1182/bloodadvances.2021005621
Published: 2022
Includes: Supplemental data